BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tian Z, Liu M, Zhang Y, Wang X. Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies. J Hematol Oncol 2021;14:75. [PMID: 33941237 DOI: 10.1186/s13045-021-01084-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Vlachonikola E, Stamatopoulos K, Chatzidimitriou A. T Cell Defects and Immunotherapy in Chronic Lymphocytic Leukemia. Cancers (Basel) 2021;13:3255. [PMID: 34209724 DOI: 10.3390/cancers13133255] [Reference Citation Analysis]
2 Garcia-Lacarte M, Grijalba SC, Melchor J, Arnaiz-Leché A, Roa S. The PD-1/PD-L1 Checkpoint in Normal Germinal Centers and Diffuse Large B-Cell Lymphomas. Cancers (Basel) 2021;13:4683. [PMID: 34572910 DOI: 10.3390/cancers13184683] [Reference Citation Analysis]
3 Liu C, Zhang G, Xiang K, Kim Y, Lavoie RR, Lucien F, Wen T. Targeting the immune checkpoint B7-H3 for next-generation cancer immunotherapy. Cancer Immunol Immunother 2021. [PMID: 34739560 DOI: 10.1007/s00262-021-03097-x] [Reference Citation Analysis]
4 De Bousser E, Callewaert N, Festjens N. T Cell Engaging Immunotherapies, Highlighting Chimeric Antigen Receptor (CAR) T Cell Therapy. Cancers (Basel) 2021;13:6067. [PMID: 34885176 DOI: 10.3390/cancers13236067] [Reference Citation Analysis]
5 Razeghian E, Nasution MKM, Rahman HS, Gardanova ZR, Abdelbasset WK, Aravindhan S, Bokov DO, Suksatan W, Nakhaei P, Shariatzadeh S, Marofi F, Yazdanifar M, Shamlou S, Motavalli R, Khiavi FM. A deep insight into CRISPR/Cas9 application in CAR-T cell-based tumor immunotherapies. Stem Cell Res Ther 2021;12:428. [PMID: 34321099 DOI: 10.1186/s13287-021-02510-7] [Reference Citation Analysis]
6 Rodak A, Stadlmayr G, Stadlbauer K, Lichtscheidl D, Bobbili MR, Rüker F, Wozniak-Knopp G. Bispecific T-Cell Engagers Targeting Membrane-Bound IgE. Biomedicines 2021;9:1568. [PMID: 34829798 DOI: 10.3390/biomedicines9111568] [Reference Citation Analysis]
7 Bajwa A, Voorhees TJ, Kittai AS. Cellular Therapy Advances in Chronic Lymphocytic Leukemia and Richter's Syndrome. Curr Probl Cancer 2021;:100827. [PMID: 34991902 DOI: 10.1016/j.currproblcancer.2021.100827] [Reference Citation Analysis]
8 Kamakura D, Asano R, Yasunaga M. T Cell Bispecific Antibodies: An Antibody-Based Delivery System for Inducing Antitumor Immunity. Pharmaceuticals (Basel) 2021;14:1172. [PMID: 34832954 DOI: 10.3390/ph14111172] [Reference Citation Analysis]
9 Hao F, Sholy C, Wang C, Cao M, Kang X. The Role of T Cell Immunotherapy in Acute Myeloid Leukemia. Cells 2021;10:3376. [PMID: 34943884 DOI: 10.3390/cells10123376] [Reference Citation Analysis]